SCHEMBL2783371

SCHEMBL2783371

CCC(=CCCC(O)(CC)CC)c1cccc(COc2ccc(CO)c(CO)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
VDR P11473 4/20 0.57
MRGPRX4 Q96LA9 11/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
TP53 P04637 2/20 0.38
PKM P14618 2/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
RAB9A P51151 3/20 0.36
F2 P00734 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NPC1 O15118 2/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2783364 1.00 VDR (0.57) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL2783367 1.00 VDR (0.57) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6155490 0.93 VDR (0.52) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6155487 0.93 VDR (0.52) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6155480 0.93 VDR (0.52) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6155222 0.92 VDR (0.51) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6155220 0.92 VDR (0.51) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6155215 0.92 VDR (0.51) VDRMRGPRX4SMN1; SMN2TP53PKM
SCHEMBL6154682 0.92 VDR (0.68) VDRF2
SCHEMBL6154674 0.92 VDR (0.68) VDRF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090004232-A1 BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-01 US claimed
EP-1686972-B1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RES & DEV (FR) 2008-03-12 EP claimed
US-20070041910-A1 Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2007-02-22 US claimed
EP-1686972-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES Galderma Research & Development, S.N.C. (FR) 2006-08-09 EP claimed
WO-2005053666-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 WO claimed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP claimed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US claimed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP claimed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO claimed
EP-2251004-A2 Pharmaceutical or cosmetic composition and a mixed solubilisation method for the production thereof Galderma Research & Development (FR) 2010-11-17 EP disclosed
US-20090004232-A1 BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-01 US disclosed
EP-1951199-A2 PHARMACEUTICAL OR COSMETIC COMPOSITION AND A MIXED SOLUBILISATION METHOD FOR THE PRODUCTION THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-08-06 EP disclosed
EP-1952808-A2 Composition in the form of a spray comprising calcitriol GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-08-06 EP disclosed
EP-1686972-B1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RES & DEV (FR) 2008-03-12 EP disclosed
WO-2005092347-A2 ANHYDROUS PHARMACEUTICAL COMPOSITION ASSOCIATING A SILICONATED AGENT AND SOLUBILISED ACTIVE PRINCIPLE GALDERMA RESEARCH & DEVELOPMENT (FR) 2005-10-06 WO disclosed
WO-2005053666-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 WO disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070041910-A1 Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase CYP24A1, CYP2R1, VDR VDR 3/4885MRGPRX4 1709/4885SMN1; SMN2 3336/4885
US-20090004232-A1 BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF CYP19A1, CYP17A1, CYP51A1 VDR 158/4885MRGPRX4 155/4885SMN1; SMN2 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.